中国实用妇科与产科杂志

中国实用妇科与产科杂志

• 专题笔谈 • 上一篇    下一篇

CA125、HE4、ROMA及RMI在附件包块诊断中的应用价值

  

  1. 厦门大学附属第一医院妇产科，福建 厦门 361001
  • 出版日期:2020-12-02 发布日期:2020-12-03
  • 通讯作者: 陈琼华
  • 基金资助:
    国家自然科学基金面上项目（81871145）；厦门市妇科疾病研究与诊疗重点实验室建设基金；厦门市妇科肿瘤优势亚专科建设基金

Application value of CA125，HE4，ROMA and RMI in the diagnosis of adnexal masses.

  1. Department of Obstetrics and Gynecology，the First Affiliated Hospital of Xiamen University，Xiamen 361001，China
  • Online:2020-12-02 Published:2020-12-03

摘要： 附件包块病因复杂多样，相应的临床决策千差万别。因此，对附件包块性质的预判是临床诊断的首要任务，也是临床工作的难点和要点。CA125是鉴别附件包块良恶性的最常见指标，但影响因素多，不建议单独用于绝经前女性。人附睾蛋白4（HE4）特异度高，联合CA125可显著提高附件包块良恶性鉴别诊断的准确率。针对附件包块拟行手术的患者，推荐应用卵巢恶性肿瘤风险模型（ROMA）和恶性肿瘤风险指数（RMI）进行评估，高危者应转诊到妇科肿瘤专科。

关键词: 人附睾蛋白4, 癌抗原125, 卵巢恶性肿瘤风险模型, 恶性肿瘤风险指数, 附件包块

Abstract: The etiology of adnexal masses is complex and varied，and the corresponding clinical treatments vary widely. Therefore, the primary task of clinical diagnosis is to evaluate the nature of adnexal masses，which is also the difficult and focal point. Cancer antigen 125（CA125）is the most common marker to distinguish benign and malignant adnexal masses，since there are many influence factors, it is not recommended to use CA125 alone in premenopausal women. Human epididymal protein 4（HE4）has better specificity and the combination with CA125 can significantly improve the accuracy of differentiating benign from malignant adnexal mass. Risk of Ovarian Malignancy Algorithm （ROMA）and Risk of Malignancy Index（RMI）are recommended to use in evaluating the patients with adnexal masses before surgery. High-risk patients should warrant referral to a gynecologic oncologist.

Key words: HE4, CA125, ROMA, RMI, adnexal masses

中图分类号: